XNYS · Healthcare · Drug Manufacturers - General
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | 0.87 | -0.00 | -100.23% | $0 | ❌ Miss | +0.13% | -4.27% | — |
| 2026-05-06 | Q1 2026 | 0.87 | 1.04 | +19.31% | $15.17B | ✅ Beat | +7.20% | +2.88% | — |
| 2026-02-04 |
| Q4 2025 |
| 0.89 |
| 1.00 |
| +12.36% |
| $12.34B |
| ✅ Beat |
| -5.37% |
| +3.28% |
| -18.25% |
| 2025-11-05 | Q3 2025 | 0.77 | 1.03 | +33.38% | $11.74B | ✅ Beat | — | — | — |
| 2025-08-06 | Q2 2025 | 0.93 | 0.91 | -2.15% | $11.68B | ❌ Miss | — | — | — |
| 2025-02-05 | Q4 2024 | 0.83 | 0.91 | +9.64% | $12.26B | ✅ Beat | +1.68% | -4.60% | +1.68% |
| 2024-11-06 | Q3 2024 | 0.88 | 0.90 | +2.27% | $10.50B | ✅ Beat | +2.15% | +1.47% | +5.13% |
| 2024-08-07 | Q2 2024 | 0.69 | 0.65 | -5.80% | $9.82B | ❌ Miss | +7.50% | +12.74% | +9.99% |
Showing last 8 quarters.